Bioconjugate development continues to be a markedly complex proposition for drug developers, driven, in part, by increasingly intricate, disparate supply chains and a pervasive lack of expertise across the biotherapeutic sector. Iwan Bertholjotti, Director of Commercial Development of Bioconjugates, and Dr. Bernhard Stump, Head of Development of Bioconjugates, recently hosted a Q&A session after their webinar The Challenges of Moving a Bioconjugate Candidate from Clinic to Market. Here you can read the questions they addressed from attendees regarding Lonza’s expertise and history in this space.
Latest content